학술논문
First international workshop of the ATM and cancer risk group (4-5 December 2019).
Document Type
Academic Journal
Author
Lesueur F; Genetic Epidemiology of Cancer Team, INSERM U900, Institut Curie, 26 rue d'Ulm, 75005, Paris, France.; Institut Curie, Paris, France.; Mines ParisTech, Fontainebleau, France.; PSL Research University, Paris, France.; Easton DF; Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK.; Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK.; Renault AL; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Tavtigian SV; Huntsman Cancer Institute, Salt Lake City, USA.; Bernstein JL; Memorial Sloan Kettering Cancer Center, New York, USA.; Kote-Jarai Z; The Institute of Cancer Research, London, UK.; Eeles RA; The Institute of Cancer Research, London, UK.; Plaseska-Karanfia D; Research Centre for Genetic Engineering and Biotechnology « Georgi D. Efremov », MASA, Skopje, UK.; Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Arun B; University of Texas MD Anderson Cancer Center, Houston, USA.; Herold N; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; Versmold B; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; Schmutzler RK; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; Nguyen-Dumont T; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Cancer Epidemiology Division, Cancer Council Victoria, Victoria, 3004, Australia.; Southey MC; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.; Cancer Epidemiology Division, Cancer Council Victoria, Victoria, 3004, Australia.; Dorling L; Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK.; Dunning AM; Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK.; Ghiorzo P; Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Genetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.; Dalmasso BS; Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Genetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.; Cavaciuti E; Genetic Epidemiology of Cancer Team, INSERM U900, Institut Curie, 26 rue d'Ulm, 75005, Paris, France.; Institut Curie, Paris, France.; Mines ParisTech, Fontainebleau, France.; PSL Research University, Paris, France.; Le Gal D; Genetic Epidemiology of Cancer Team, INSERM U900, Institut Curie, 26 rue d'Ulm, 75005, Paris, France.; Institut Curie, Paris, France.; Mines ParisTech, Fontainebleau, France.; PSL Research University, Paris, France.; Roberts NJ; Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University, Baltimore, USA.; Dominguez-Valentin M; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Rookus M; Netherlands Cancer Institute NKI, Amsterdam, The Netherlands.; Taylor AMR; Institute of Cancer and Genomic Science, University of Birmingham, Birmingham, UK.; Goldstein AM; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Bethesda, USA.; Goldgar DE; Huntsman Cancer Institute, Salt Lake City, USA.; Stoppa-Lyonnet D; Université Paris Descartes, Paris, France.; Service de Génétique, Institut Curie, Paris, France.; INSERM U830, Paris, France.; Andrieu N; Genetic Epidemiology of Cancer Team, INSERM U900, Institut Curie, 26 rue d'Ulm, 75005, Paris, France. nadine.andrieu@curie.fr.; Institut Curie, Paris, France. nadine.andrieu@curie.fr.; Mines ParisTech, Fontainebleau, France. nadine.andrieu@curie.fr.; PSL Research University, Paris, France. nadine.andrieu@curie.fr.
Source
Publisher: Springer Country of Publication: Netherlands NLM ID: 100898211 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7292 (Electronic) Linking ISSN: 13899600 NLM ISO Abbreviation: Fam Cancer Subsets: MEDLINE
Subject
Language
English
Abstract
The first International Workshop of the ATM and Cancer Risk group focusing on the role of Ataxia-Telangiectasia Mutated (ATM) gene in cancer was held on December 4 and 5, 2019 at Institut Curie in Paris, France. It was motivated by the fact that germline ATM pathogenic variants have been found to be associated with different cancer types. However, due to the lack of precise age-, sex-, and site-specific risk estimates, no consensus on management guidelines for variant carriers exists, and the clinical utility of ATM variant testing is uncertain. The meeting brought together epidemiologists, geneticists, biologists and clinicians to review current knowledge and on-going challenges related to ATM and cancer risk. This report summarizes the meeting sessions content that covered the latest results in family-based and population-based studies, the importance of accurate variant classification, the effect of radiation exposures for ATM variant carriers, and the characteristics of ATM-deficient tumors. The report concludes that ATM variant carriers outside of the context of Ataxia-Telangiectasia may benefit from effective cancer risk management and therapeutic strategies and that efforts to set up large-scale studies in the international framework to achieve this goal are necessary.
(© 2021. The Author(s), under exclusive licence to Springer Nature B.V.)
(© 2021. The Author(s), under exclusive licence to Springer Nature B.V.)